Related Experiment Video

Updated: Aug 4, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.7K

IDO blockade negatively regulates the CTLA-4 signaling in breast cancer cells

Parviz Azimnasab-Sorkhabi1, Maryam Soltani-Asl2, Túlio Teruo Yoshinaga2

  • 1Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of Sao Paulo, Sao Paulo, Brazil. Sorkhabi.parviz@gmail.com.

Immunologic Research
|April 4, 2023
PubMed

Insights

The study reveals that blocking the indoleamine-2,3-dioxygenase (IDO) enzyme hinders the effectiveness of anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) immunotherapy in breast cancer. This suggests a molecular interaction impacting treatment efficacy.

Area of Science:

  • Immunology
  • Cancer Biology
  • Metabolic Disorders

Background:

  • Cancer involves metabolic and genetic disruptions, with tryptophan catabolism playing a key role.
  • The cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptor and indoleamine-2,3-dioxygenase (IDO) enzyme are implicated in cancer progression.

Purpose of the Study:

  • To investigate the molecular interaction between CTLA-4 and IDO in breast cancer.
  • To assess the impact of anti-CTLA-4 immunotherapy on cancer cell migration and survival.
  • To determine how IDO activity influences the efficacy of anti-CTLA-4 therapy.

Main Methods:

  • In vitro assays were used to evaluate breast cancer cell migration and survival.
  • Flow cytometry assessed the impact of anti-CTLA-4 antibody on IDO-positive cells.
  • IDO was pharmacologically blocked using 1-Methyl-DL-tryptophan (1MT) to study its effect on anti-CTLA-4 efficacy.

Main Results:

  • Anti-CTLA-4 antibody reduced breast cancer cell migration and clonogenic abilities.
  • Anti-CTLA-4 antibody did not alter the percentage of IDO-positive cancer cells.
  • Blocking IDO with 1MT diminished the effectiveness of anti-CTLA-4 antibody on cell migration and survival.

Conclusions:

  • An inhibitory molecular interaction exists between CTLA-4 and IDO functions.
  • IDO enzymatic activity negatively impacts anti-CTLA-4 immunotherapy efficacy.
  • Further research into the CTLA-4 and IDO molecular interplay is crucial for improving immunotherapy outcomes.
Keywords:
1MTAnti-CTLA-4 antibodyBreast cancerCTLA-4IDO

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
598
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
188
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K